Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Research article

Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links

Boualem Sendid12*, Angélique Cotteau3, Nadine François1, Annie D'Haveloose3, Annie Standaert1, Daniel Camus2 and Daniel Poulain12

Author Affiliations

1 Inserm, U799, Lille, F-59045 France;Laboratoire de Mycologie Fondamentale et Appliquée, Faculté de Médecine, Lille, F-59045, France

2 Laboratoire de Parasitologie-Mycologie, CHRU, Lille, F-59045, France

3 Département de Pharmacie, CHRU, Lille, F-59045 Lille, France

For all author emails, please log on.

BMC Infectious Diseases 2006, 6:80  doi:10.1186/1471-2334-6-80

Published: 2 May 2006



Evidence for an increased prevalence of candidaemia and for high associated mortality in the 1990s led to a number of different recommendations concerning the management of at risk patients as well as an increase in the availability and prescription of new antifungal agents. The aim of this study was to parallel in our hospital candidemia incidence with the nature of prescribed antifungal drugs between 1993 and 2003.


During this 10-year period we reviewed all cases of candidemia, and collected all the data about annual consumption of prescribed antifungal drugs


Our centralised clinical mycology laboratory isolates and identifies all yeasts grown from blood cultures obtained from a 3300 bed teaching hospital. Between 1993 and 2003, 430 blood yeast isolates were identified. Examination of the trends in isolation revealed a clear decrease in number of yeast isolates recovered between 1995–2000, whereas the number of positive blood cultures in 2003 rose to 1993 levels. The relative prevalence of Candida albicans and C. glabrata was similar in 1993 and 2003 in contrast to the period 1995–2000 where an increased prevalence of C. glabrata was observed. When these quantitative and qualitative data were compared to the amount and type of antifungal agents prescribed during the same period (annual mean defined daily dose: 2662741; annual mean cost: 615629 €) a single correlation was found between the decrease in number of yeast isolates, the increased prevalence of C. glabrata and the high level of prescription of fluconazole at prophylactic doses between 1995–2000.


Between 1993 and 2000, the number of cases of candidemia halved, with an increase of C. glabrata prevalence. These findings were probably linked to the use of Fluconazole prophylaxis. Although it is not possible to make any recommendations from this data the information is nevertheless interesting and may have considerable implications with the introduction of new antifungal drugs.